379 related articles for article (PubMed ID: 16153895)
1. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
Muro S; Schuchman EH; Muzykantov VR
Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
[TBL] [Abstract][Full Text] [Related]
2. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement.
Rappaport J; Garnacho C; Muro S
Mol Pharm; 2014 Aug; 11(8):2887-95. PubMed ID: 24949999
[TBL] [Abstract][Full Text] [Related]
3. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
4. Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.
Rappaport J; Manthe RL; Garnacho C; Muro S
Mol Pharm; 2015 May; 12(5):1366-76. PubMed ID: 25849869
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.
Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S
Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376
[TBL] [Abstract][Full Text] [Related]
6. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
[TBL] [Abstract][Full Text] [Related]
7. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
8. The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor.
Ni X; Morales CR
Traffic; 2006 Jul; 7(7):889-902. PubMed ID: 16787399
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
[TBL] [Abstract][Full Text] [Related]
10.
Manthe RL; Rappaport JA; Long Y; Solomon M; Veluvolu V; Hildreth M; Gugutkov D; Marugan J; Zheng W; Muro S
J Pharmacol Exp Ther; 2019 Sep; 370(3):823-833. PubMed ID: 31101681
[TBL] [Abstract][Full Text] [Related]
11. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.
Dodge JC; Clarke J; Treleaven CM; Taksir TV; Griffiths DA; Yang W; Fidler JA; Passini MA; Karey KP; Schuchman EH; Cheng SH; Shihabuddin LS
Exp Neurol; 2009 Feb; 215(2):349-57. PubMed ID: 19059399
[TBL] [Abstract][Full Text] [Related]
12. Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier.
Loeck M; Placci M; Muro S
Drug Deliv Transl Res; 2023 Dec; 13(12):3077-3093. PubMed ID: 37341882
[TBL] [Abstract][Full Text] [Related]
13. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
[TBL] [Abstract][Full Text] [Related]
14. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
15. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease.
Passini MA; Macauley SL; Huff MR; Taksir TV; Bu J; Wu IH; Piepenhagen PA; Dodge JC; Shihabuddin LS; O'Riordan CR; Schuchman EH; Stewart GR
Mol Ther; 2005 May; 11(5):754-62. PubMed ID: 15851014
[TBL] [Abstract][Full Text] [Related]
16. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Hsu J; Northrup L; Bhowmick T; Muro S
Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
[TBL] [Abstract][Full Text] [Related]
17. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.
Hsu J; Hoenicka J; Muro S
Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100
[TBL] [Abstract][Full Text] [Related]
18. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells.
Suchi M; Dinur T; Desnick RJ; Gatt S; Pereira L; Gilboa E; Schuchman EH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3227-31. PubMed ID: 1565614
[TBL] [Abstract][Full Text] [Related]
19. Enhanced delivery to endothelial lysosomes by ICAM-1-targeted nanocarriers.
Park K
J Control Release; 2011 Feb; 149(3):207-8. PubMed ID: 21238515
[No Abstract] [Full Text] [Related]
20. Niemann-Pick type C disease: novel NPC1 mutations and characterization of the concomitant acid sphingomyelinase deficiency.
Tamura H; Takahashi T; Ban N; Torisu H; Ninomiya H; Takada G; Inagaki N
Mol Genet Metab; 2006 Feb; 87(2):113-21. PubMed ID: 16143556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
